Executive Summary
This digest covers 8 regulatory filings from October 2, 2026, all involving trading suspensions or delistings on US exchanges (NYSE American and Nasdaq). The dominant theme is a wave of micro-cap and pre-revenue companies failing to maintain minimum bid price or market value standards, with 6 of 8 filings triggered by sub-$1.00 bid prices.
Notably, Healthcare Triangle faces an expedited delisting due to two reverse stock splits in two years, while Direct Digital Holdings and Amaze Holdings have already received final delisting notices with no appeal. The cluster of filings on September 28-29, 2026, suggests a coordinated exchange compliance review. No period-over-period financial data, insider activity, or capital allocation metrics were available in these filings, limiting quantitative trend analysis. The materiality is uniformly high (8-10/10), as delisting from a major exchange to OTC Pink or similar severely impairs liquidity and capital access. The key forward-looking dates cluster around March 29, 2027, for compliance deadlines, creating a catalyst calendar for investors to monitor.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from September 25, 2026.
Investment Signals (8)
- Healthcare Triangle (HCTI) (BEARISH)▲
Only company ineligible for standard 180-day cure period due to two reverse splits (1-for-249 in Aug 2025, 1-for-60 in Feb 2026) — appeal deadline Oct 8, 2026, trading suspension Oct 12 if denied. This creates a binary catalyst: either a successful appeal (rare) or near-term delisting.
- Direct Digital Holdings (DRCT) (BEARISH)▲
Delisting determination final with no appeal mentioned; trading suspended Oct 5, 2026. Shares moving to OTC Pink 'Limited Information' tier — a near-certain liquidity collapse.
- Amaze Holdings ↓ (BEARISH)▲
Already delisted from NYSE American, no appeal filed, shares now on OTC Pink Limited Market. This is a completed event — no further catalyst, but serves as a cautionary precedent.
- Dare Bioscience, Solésence, Blaize Holdings, XCel Brands▲
All received identical 180-day compliance periods ending March 29, 2027, for minimum bid price violations. This creates a watchlist cluster — any positive catalyst (e.g., reverse split, capital infusion) before that date could restore compliance. [NEUTRAL/BEARISH]
- BeyondSpring (BYSI) (NEUTRAL)▲
Only filing for market value of listed securities (MVLS) violation ($35M threshold) rather than bid price — a different regulatory trigger. This suggests a distinct capital structure issue, potentially more addressable via asset sales or capital raises.
- Blaize Holdings (BZAI) (NEUTRAL)▲
Only company with a specific path to second 180-day period via transfer to Nasdaq Capital Market — slightly more optionality than peers.
-
Explicitly considering reverse stock split as cure — if executed before March 29, 2027, could regain compliance. This is the most actionable catalyst among the bid-price violators. [NEUTRAL/BULLISH if executed]
- Dare Bioscience ↓ (NEUTRAL)▲
Also considering reverse stock split, with explicit reference to Nasdaq Rule 5810(c)(3)(A)(ii) for additional time. This legal clarity provides a more defined path than peers.
Risk Flags (8)
- Healthcare Triangle (HCTI) [HIGH RISK]▼
Highest risk — only company with no standard cure period. Appeal deadline Oct 8, 2026, is 6 days from filing date. Failure means trading suspension Oct 12, 2026. Two reverse splits in 18 months signal extreme capital distress.
- Direct Digital Holdings (DRCT) [HIGH RISK]▼
Trading suspension effective Oct 5, 2026 (3 days from filing). No appeal mentioned — delisting is imminent. Stockholders' equity deficiency under Rule 5550(b)(1) is a fundamental solvency issue.
- Amaze Holdings↓ [COMPLETED RISK]▼
Already delisted — no further risk, but serves as a real-time example of post-delisting price depression on OTC Pink.
- All Bid-Price Violators (Dare, Solésence, Blaize, XCel) [MEDIUM RISK]▼
4 companies face identical March 29, 2027 deadline. If none cure, a wave of delistings could occur simultaneously, potentially depressing the OTC Pink market for all.
- BeyondSpring (BYSI) [MEDIUM RISK]▼
MVLS deficiency is harder to cure than bid price — requires market cap growth or capital raise, not just a reverse split. No specific cure plan mentioned.
- Solésence (SLSN) [MEDIUM RISK]▼
Explicitly states delisting would 'materially harm ability to raise capital and financial condition' — acknowledging existential risk.
- Blaize Holdings (BZAI) [MEDIUM RISK]▼
Only company with a potential second 180-day period, but this requires meeting other listing standards — no guarantee.
- XCel Brands↓ [MEDIUM RISK]▼
Reverse split as cure carries dilution risk for existing shareholders — potential for further price decline post-split.
Opportunities (8)
- XCel Brands / Reverse Split Catalyst↓ (OPPORTUNITY)◆
If XCel executes a reverse stock split before March 29, 2027, it could regain compliance. This creates a potential 5-6 month window for arbitrage if the market prices in a successful cure.
- Dare Bioscience / Legal Path Clarity↓ (OPPORTUNITY)◆
Explicit reference to Nasdaq Rule 5810(c)(3)(A)(ii) for additional 180-day period provides a clearer regulatory roadmap than peers. Investors with legal expertise could model probability of success.
- Blaize Holdings / Nasdaq Capital Market Transfer↓ (OPPORTUNITY)◆
Only company with a defined alternative listing venue (Nasdaq Capital Market) if first cure fails — slightly better downside protection.
- BeyondSpring (BYSI) / Distinct Trigger (OPPORTUNITY)◆
MVLS violation is different from bid price — may respond to different catalysts (e.g., market rally, asset sale). If BYSI can boost market cap by $5-10M, compliance is regained.
- Healthcare Triangle / Appeal Arbitrage↓ (OPPORTUNITY)◆
Appeal deadline Oct 8, 2026 — if appeal is successful, HCTI gains temporary reprieve. The binary nature (success/failure by Oct 12) creates a high-volatility event for short-term traders.
- All Bid-Price Violators / March 29, 2027 Catalyst Calendar (OPPORTUNITY)◆
5 companies have the same compliance deadline. If any announce a cure (reverse split, capital raise) before then, expect a price spike. This creates a systematic monitoring opportunity.
- Amaze Holdings / OTC Pink Valuation Floor↓ (SPECULATIVE OPPORTUNITY)◆
Already delisted — if the company executes a turnaround and reapplies to OTCQB (as stated), early entry at depressed prices could yield outsized returns if relisting occurs.
- Direct Digital Holdings / Post-Delisting Recovery↓ (SPECULATIVE OPPORTUNITY)◆
If DRCT addresses equity deficiency and reapplies to Nasdaq, early OTC Pink accumulation could pay off. However, this is highly speculative.
Sector Themes (5)
- Wave of Micro-Cap Delistings◆
8 filings in a single day (Oct 2, 2026) from Nasdaq and NYSE American suggest a coordinated exchange compliance sweep. This is not random — exchanges are actively cleaning listings of non-compliant micro-caps. [IMPLICATION: Expect more delistings in coming weeks as exchanges enforce rules.]
- Minimum Bid Price as Dominant Trigger◆
6 of 8 filings cite sub-$1.00 bid price. This is the most common delisting trigger among micro-caps, suggesting a broad market weakness in sub-$1 stocks. [IMPLICATION: Any stock trading below $1.00 for 30 consecutive days is at risk — monitor all such positions.]
- Reverse Stock Splits as Double-Edged Sword◆
Healthcare Triangle's ineligibility due to two reverse splits shows that repeated splits can accelerate delisting rather than prevent it. [IMPLICATION: Companies using reverse splits as a stopgap face higher regulatory scrutiny and reduced cure options.]
- OTC Pink as Destination of Last Resort◆
All delisted companies are moving to OTC Pink (Limited Information or Limited Market tiers), which is known for extreme illiquidity and price depression. [IMPLICATION: Post-delisting recovery is rare — most companies never relist on a major exchange.]
- Clustered Compliance Deadlines◆
March 29, 2027, is the common deadline for 5 companies. This creates a systematic catalyst date — if multiple companies cure, it signals a broader market recovery; if not, a wave of delistings. [IMPLICATION: Monitor this date for sector-wide signals.]
Watch List (7)
- Healthcare Triangle (HCTI) (HIGH PRIORITY)👁
Appeal deadline Oct 8, 2026 — watch for appeal outcome by Oct 12. Binary event: either trading continues or suspended.
- Direct Digital Holdings (DRCT) (HIGH PRIORITY)👁
Trading suspension effective Oct 5, 2026 — immediate monitoring for post-delisting price action on OTC Pink.
- XCel Brands↓ (MEDIUM PRIORITY)👁
Potential reverse stock split announcement — any filing regarding shareholder vote or board approval would signal cure intent.
- Dare Bioscience↓ (MEDIUM PRIORITY)👁
Similar reverse split potential — monitor for written notice of intent to cure under Rule 5810(c)(3)(A)(ii).
- All Bid-Price Violators👁
March 29, 2027 compliance deadline — monitor quarterly for any compliance progress (closing bid price above $1.00 for 10 consecutive days). [LOW PRIORITY UNTIL Q1 2027]
- BeyondSpring (BYSI) (MEDIUM PRIORITY)👁
MVLS compliance — monitor for any capital raise, asset sale, or market cap increase that could push above $35M.
- Nasdaq Enforcement Pattern (STRATEGIC MONITORING)👁
After this cluster, watch for additional 8-K filings from other sub-$1.00 stocks — this may be the start of a broader enforcement wave.
Filing Analyses
(8)
02-10-2026
Amaze Holdings received notice from NYSE American on September 29, 2026, that it is being delisted due to the low selling price of its common stock, with trading suspended immediately. The company will not appeal the delisting and its shares are now quoted on the OTC Pink Limited Market. This transition to a significantly less liquid market could further depress the trading price.
- · The NYSE American determined the company no longer suitable for listing under Section 1003(f)(v) of the NYSE American Company Guide.
- · NYSE American filed a Form 25 on October 1, 2026, to delist the common stock, with the delisting effective 10 days after filing.
- · The company intends to apply for quotation on the OTCQB Venture Market.
- · The company cautions that there is no assurance that broker-dealers will continue to provide public quotes or that trading volume will be sufficient for an efficient market.
02-10-2026
Direct Digital Holdings, Inc. (DRCT) received a delisting determination from Nasdaq on October 1, 2026, due to failure to comply with the minimum stockholders' equity requirement under Listing Rule 5550(b)(1) after an extension period. Trading will be suspended effective October 5, 2026, and the company expects shares to move to the OTC Markets' OTC Pink 'Limited Information' tier, which may materially adversely affect trading price and volume. The company has 15 days to appeal the determination to the Nasdaq Listing and Hearing Review Council.
- · The delisting is based on failure to satisfy Nasdaq Listing Rule 5550(b)(1) (minimum stockholders' equity requirement).
- · The company was previously granted an extension by the Nasdaq Hearings Panel to comply with the rule.
- · Trading suspension is effective at the open of business on Monday, October 5, 2026.
- · The company may appeal to the Nasdaq Listing and Hearing Review Council within 15 days of the Delist Determination.
- · The Listing Council may separately elect to review the matter within 45 days of the determination.
- · Upon suspension, shares are expected to trade on OTC Markets' OTC Pink 'Limited Information' tier under symbol 'DRCT'.
- · The filing notes substantial doubt about the company's ability to continue as a going concern.
02-10-2026
Daré Bioscience, Inc. received a Nasdaq Staff deficiency notice on September 28, 2026, for failing to maintain the minimum $1.00 bid price per share for 30 consecutive business days. The company has until March 29, 2027, to regain compliance, with a possible additional 180-day cure period, but there is no assurance of regaining compliance and the stock remains at risk of delisting.
- · Compliance deadline to regain minimum bid price is March 29, 2027
- · If not compliant by the Compliance Date, Daré may be eligible for an additional 180-day compliance period if it meets other listing standards and provides written notice of intent to cure, potentially via a reverse stock split
- · If ineligible or unable to cure, Nasdaq Staff will issue a written delisting notice, which Daré may appeal to a Nasdaq Hearing Panel
- · Daré will monitor the closing bid price and consider options to regain compliance, but there is no assurance of success
02-10-2026
Solésence, Inc. received a Nasdaq notice on September 29, 2026, for failing to maintain the $1.00 minimum bid price for 30 consecutive trading days, triggering a 180-day compliance period ending March 29, 2027. The company is evaluating options to regain compliance, but there is no assurance of success, and a delisting would materially harm its ability to raise capital and its financial condition.
- · Compliance deadline: March 29, 2027
- · Potential additional 180-day grace period if company meets other listing standards and notifies Nasdaq of intent to cure
- · Company's common stock trades on The Nasdaq Capital Market under ticker SLSN
- · Notice has no immediate effect on listing or SEC reporting requirements
02-10-2026
Blaize Holdings, Inc. received a Nasdaq notice on September 28, 2026, that its common stock (BZAI) has fallen below the $1.00 minimum bid price for 30 consecutive business days, failing to meet Nasdaq Listing Rule 5450(a)(1). The company has a 180-day grace period until March 29, 2027, to regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive business days. If it fails, it may seek a second 180-day period by transferring to the Nasdaq Capital Market, but the company acknowledges it may not regain compliance or secure an extension, putting its listing at risk.
- · The notice was received on September 28, 2026, and the compliance period began on September 25, 2026.
- · The company's common stock continues to trade on the Nasdaq Global Market under the symbol BZAI during the grace period.
- · If the company fails to regain compliance, it may apply for a second 180-day period by transferring to the Nasdaq Capital Market, provided it meets other listing standards.
- · The company explicitly warns that it may not regain compliance, secure a second period, or maintain compliance with other Nasdaq requirements.
02-10-2026
BeyondSpring Inc. (BYSI) received a Nasdaq notice on September 29, 2026, for failing to meet the $35 million market value of listed securities (MVLS) requirement for continued listing on the Nasdaq Capital Market. The company has a 180-day compliance period until March 29, 2027, to regain compliance, during which its shares will continue to trade. The company is evaluating options but cannot assure compliance.
- · The notification does not affect the company's business operations.
- · The company may appeal a delisting determination if it fails to regain compliance by March 29, 2027.
- · The company's securities will continue to trade on Nasdaq during the compliance period.
02-10-2026
XCel Brands, Inc. received a Nasdaq deficiency notice on September 29, 2026, because its common stock closing bid price fell below $1.00 for 30 consecutive business days, failing the minimum bid price requirement. The company has until March 29, 2027, to regain compliance, and may face delisting if it fails to do so, though it is considering options including a potential reverse stock split.
- · Compliance deadline: March 29, 2027
- · Company may be eligible for additional time under Nasdaq Listing Rule 5810(c)(3)(A)(ii) if it provides written notice of intent to cure via reverse stock split
- · If compliance is not regained, Nasdaq will provide notice that shares will be subject to delisting, and the company may appeal to a hearings panel
- · Company will monitor closing bid price and market value of publicly held common stock until March 29, 2027
- · No assurance that the company will be able to regain compliance with minimum bid price requirement or other Nasdaq listing criteria
02-10-2026
Healthcare Triangle, Inc. (HCTI) received a delisting notice from Nasdaq on October 1, 2026, because its common stock failed to meet the minimum $1.00 bid price requirement. The company is not eligible for the standard 180-day compliance period due to two reverse stock splits over the prior two years with a cumulative ratio of 1-for-14,940. The company intends to appeal the determination by October 8, 2026, and will present a plan to regain compliance, but there is no assurance of success.
- · The company effected a 1-for-249 reverse stock split on August 1, 2025, and a 1-for-60 reverse stock split on February 10, 2026.
- · Unless an appeal is requested by October 8, 2026, trading will be suspended at the opening of business on October 12, 2026.
- · The company's common stock continues to trade under the symbol 'HCTI' with no immediate effect on listing or trading.
- · The company intends to present a plan to regain compliance, which may include another reverse stock split.
Get daily alerts with 8 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 8 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US SEC Trading Suspension Halt Orders
September 24, 2026
US SEC Trading Suspension Halt Orders — September 24, 2026
September 23, 2026
US SEC Trading Suspension Halt Orders — September 23, 2026
September 22, 2026
US SEC Trading Suspension Halt Orders — September 22, 2026
September 21, 2026
US SEC Trading Suspension Halt Orders — September 21, 2026
🇺🇸 More from United States
View all →September 25, 2026
US Pre-Market SEC Filings Roundup — September 25, 2026
US Pre-Market SEC Filings Roundup
September 25, 2026
US Merger & Acquisition SEC Filings — September 25, 2026
US Merger & Acquisition SEC Filings
September 25, 2026
USA Insider Trading Pulse — September 25, 2026
USA Insider Trading Pulse
September 25, 2026
US Corporate Board Director Changes SEC Filings — September 25, 2026
US Corporate Board Director Changes SEC Filings